Debiopharm S.A.
http://www.debiopharm.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Debiopharm S.A.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.
Rising Up In Biopharma: Optimism, AI And Perseverance
Ahead of In Vivo’s 2024 Rising Leaders list being revealed in April, a panel of biopharma leaders discussed industry trends and biopharma career stories at BIO-Europe Spring.
UroGen Approaches A Big Expansion In Bladder Cancer
The oncology company is preparing for the launch of UGN-102 for bladder cancer. CEO Liz Barrett talked to Scrip about the company’s next growth phase.
Deal Watch: Bristol To Link Up With VantAI On Molecular Glue Therapies
Plus deals involving BioVaxys/IMV, Immunome/Ayala, Nascent/Manhattan BioSolutions, AVROBIO/Tectonic, Sanofi/Synthekine, NAYA/Florida Biotechnologies as well as deals in brief and tech transfer agreements.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Drug Delivery
- Other Names / Subsidiaries
-
- H3 Pharma
- Affinium Pharmaceuticals, Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice